Author: Amin et al. Summary: The escalating global prevalence of type 2 diabetes mellitus (T2DM) with its associated healthcare burden necessitate the innovation of effective and adaptable treatment approaches. Omarigliptin, a once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, has been demonstrated with promising outcomes in the management of T2DM in clinical trials conducted across the world. This study aims to assess the real-world effectiveness and safety of omarigliptin in the management of newly diagnosed T2DM clinical settings in Bangladesh. This observational study will be conducted at BIRDEM General Hospital in Bangladesh over a period of 12 months. Individuals aged 18 years or